The early in vivo studies in rat models of hepatic fibrosis also showed antifibrotic effects, but in all cases, these were prevention studies in which the treatment with the PPARγ agonists was begun prior to, or concomitantly with, the induction of fibrosis [6,7,8,9,10,11]. Here, PPARG is linked to Hepatic fibrosis.